With over 12 years of experience spanning global regulatory affairs, drug development, and clinical research, Odette brings a wealth of expertise—particularly in advancing innovative therapies for rare and underserved diseases. Her career has been shaped by a deep commitment to ensuring that novel treatments are both effective and safe, especially for vulnerable populations including children.

Reetu Gupta is Chair of the Health Scientific Board at the Maroon Research Institute, where she leads initiatives at the intersection of women’s health, healthy longevity, and climate-driven determinants of health. She also serves as the Head of California & India Partnerships & Community for the Institute. Reetu is a seasoned strategic leader reflecting a 20+ year track record in healthcare, finance, and is passionate about how Climate has a direct impact on Health. Previously Vice President Customer Success at Brightline Health and 10+ year tenure at Kaiser Permanente, encompassing new program development, strategic partnerships and M&A.  She brings her healthcare and innovation experience advising purpose-driven founders.

She have successfully founded and scaled institutional firms and ventures; establishing a track record globally over 20+ years as a transformative leader, astute institutional investor; arranger (US$30bn+); and catalytic entrepreneur across private credit and growth equity (as both GP & Limited Partner)Managing Partner for Maroon Venture Fund I LP investing anchor capital to advance Health span & Longevity Science by closing material innovation & funding gaps in proactive, personalized Preventative Health for chronic Population Health conditions and direct Climate impact on Health. Coming from an innovative, very successful, multi-generational family business in Precision Medicine, Genetics & Preventative Health, I have an intrinsic respect & commitment to addressing single digit statistics undermining early detection, diagnosis & prevention of chronic Pop. Health conditions

Trevor Wilkins is a career-long founder, operator, investor, and coach in the early-stage ventures space. A former Forbes 30 Under 30 Nominee, Trevor relocated to Los Angeles as an investor for Quake Capital to help establish their local office. During the pandemic, he served as the VP of Partner Engagement at ScaleHealth, a health innovation marketplace, where he connected payer, provider, and pharma organizations with agile startups. Currently, Trevor leads monthly fireside chats on health tech market trends while helping healthcare startups navigate go-to-market strategies and business operations.

Naseeha Machingal is Senior Director of Client Success & Partnerships at Legal Ease Solutions, a leading Alternative Legal Service Provider specializing in legal consulting and solutions. She leads a global team across the US and India, managing strategic partnerships and driving revenue growth for the company's largest client portfolio. With over 7 years of experience building client success programs, scaling service delivery models, and navigating complex enterprise partnerships, Naseeha brings a practitioner's perspective on what it takes to grow a services business by putting clients at the center. She is also an avid mountaineer who has summited Kilimanjaro, Mount Whitney, and Pikes Peak.

Matthew Rota is the Vice President of Operations at Repeat Therapeutics, where he leads company programs with a focus on execution, early-stage development, and cross-functional strategy. His background spans drug development, technology transfer, and commercial operations, with prior roles at Catalent Pharma Solutions and TriLink BioTechnologies. He brings a practical startup perspective on how emerging health companies can move from promising science to scalable impact.

Sabrina Maisel, PhD, is a translational scientist and strategic leader with nearly 15 years of experience spanning drug and assay development, cell-based therapeutics, and oncology. Some of her previous work in regenerative medicine and hair follicle biology centered on developing novel cell-based therapies, advancing areas of medicine that have historically been underfunded and underserved. Currently, Sabrina serves as an investor and resident Subject Matter Expert with NuFund Venture Group, contributing to early-stage investment decisions and supporting companies with the potential to drive meaningful change, particularly those with the potential to improve outcomes for women across all stages of life.

Max Gottschalk is a venture capital and private equity investor with over 30 years of experience building and leading global investment businesses. He is Managing Partner of the Clinique La Prairie Longevity Fund, a EUR 300M vehicle investing at the intersection of Medical Care, Nutrition, Movement, and Wellbeing. Max began his career at Bear Stearns before co-founding Gottex Fund Management in 1998, scaling it to $16 billion AUM and listing it on the Swiss Stock Exchange in 2007. He subsequently founded Vedra Partners, a multi-family office, and co-founded a series of impact-focused funds including Ocean 14 Capital and Hycap. He is also Non-Executive Chairman of Perfect Moment (NYSE: PMNT). A longstanding advocate for investing where science and human wellbeing converge, Max holds a Business degree in Finance from the University of Virginia's McIntire School of Commerce, where he chairs the International Board and has taught Global Impact Investing.

‍

Iyas Seidan is the Managing Partner of Ember Consulting Group, an accomplished leader with extensive experience in Business Development, and M&A across EMEA, Asia Pacific and US. Known for his solid leadership, results-driven approach, and efficiency-conscious mindset, he excels in maximizing performance and enhancing organizational effectiveness. Mr. Seidan has a proven track record of driving strategic business expansion initiatives that enable businesses to achieve their short- and long-term targets, streamline business activities, and improve customer retention and compliance rates. His career is marked by numerous awards for successful implementations and transformative leadership.

‍

Loretta TIOIELA is the co-founder & Managing Partner of Next Sequence, a SF and Paris based venture firm. She is a technologist with more than 15 years of experience in Cloud and A.I. technologies and worked for major industry players such as Samsung Electronics and Huawei Technologies as well as startups. Among many technologies, she has chosen to put her faith in the belief that the future will be shaped by the convergence of life science and computing technologies and now support and invest in companies building a future powered by AI and Biology.

‍

Eva Wang, Ph.D., MBA, is a biotechnology executive and investor with over two decades of experience at the intersection of life sciences, data science, and AI. With a strong operational track record, she has held senior leadership roles across multiple startups, contributing directly to three IPOs and two acquisitions. Dr. Wang began her career in protein structure modelling and genomics alongside Nobel laureate Michael Levitt. Today, she integrates her Ph.D. in Computer Science (UC Santa Cruz), MBA (The Wharton School), and B.S. in Microbiology to bring a unique multidisciplinary edge to evaluating companies. Currently a Venture Partner at MIH, a partner and advisor with NuFund and Wharton Alumni Angels, she is dedicated to supporting early-stage founders through both capital and mentorship.

Janele Ting is a first-year UCSD student majoring in biology with a specialization in bioinformatics and a minor in CS. She brings experience and interest in the intersectionalities of entrepreneurship, biology, and personalized medicine for women's health. She has worked closely with the San Diego Nucleate community on the operations team for the 2026incubator cohort and in business consulting roles for local San Diego biotech startups. She currently serves as a project manager for the Venture Committee of the UCSD Engineering and Innovation EntrepreneurshipClub and was selected for the Qualcomm Institute Entrepreneurshipcohort of winter 2026. This summer, she is conducting research in agentic modeling of mass spectrometry data in the Dorrestein Lab andhopes to utilize this interdisciplinary background to further propelwomen's health ventures forward.